Biotech mega-seeds are common because the science requires it, you can't run a Phase 1 trial on $3 million, but the return profile is often humbling. Large first rounds in biotech have produced a handful of strong outcomes for first-check investors ' and a very long tail of modest ones. Our experience with this trend in biotech motivated us to compile a dataset and pressure-test our intuition more broadly. We pulled every publicly available $100 million-plus first round we could find over the last 15 years (roughly 200 deals) and found that only 20% had recorded exits. Of those, only a few delivered what we'd call a venture-like return: 10x MOIC or better for the first-round investor. In other words, approximately 1% of companies that publicly raised $100 million or more in their first financing round generated returns that justify the asset class. Capital intensity, as it turns out, actually worked against venture outcomes. That distribution will improve with a few well-placed AI...
learn more
